VASARI-auto: equitable, efficient, and economical featurisation of glioma MRI
Authors:
James K Ruffle,
Samia Mohinta,
Kelly Pegoretti Baruteau,
Rebekah Rajiah,
Faith Lee,
Sebastian Brandner,
Parashkev Nachev,
Harpreet Hyare
Abstract:
The VASARI MRI feature set is a quantitative system designed to standardise glioma imaging descriptions. Though effective, deriving VASARI is time-consuming and seldom used in clinical practice. This is a problem that machine learning could plausibly automate. Using glioma data from 1172 patients, we developed VASARI-auto, an automated labelling software applied to both open-source lesion masks an…
▽ More
The VASARI MRI feature set is a quantitative system designed to standardise glioma imaging descriptions. Though effective, deriving VASARI is time-consuming and seldom used in clinical practice. This is a problem that machine learning could plausibly automate. Using glioma data from 1172 patients, we developed VASARI-auto, an automated labelling software applied to both open-source lesion masks and our openly available tumour segmentation model. In parallel, two consultant neuroradiologists independently quantified VASARI features in a subsample of 100 glioblastoma cases. We quantified: 1) agreement across neuroradiologists and VASARI-auto; 2) calibration of performance equity; 3) an economic workforce analysis; and 4) fidelity in predicting patient survival. Tumour segmentation was compatible with the current state of the art and equally performant regardless of age or sex. A modest inter-rater variability between in-house neuroradiologists was comparable to between neuroradiologists and VASARI-auto, with far higher agreement between VASARI-auto methods. The time taken for neuroradiologists to derive VASARI was substantially higher than VASARI-auto (mean time per case 317 vs. 3 seconds). A UK hospital workforce analysis forecast that three years of VASARI featurisation would demand 29,777 consultant neuroradiologist workforce hours (£1,574,935), reducible to 332 hours of computing time (and £146 of power) with VASARI-auto. The best-performing survival model utilised VASARI-auto features as opposed to those derived by neuroradiologists. VASARI-auto is a highly efficient automated labelling system with equitable performance across patient age or sex, a favourable economic profile if used as a decision support tool, and with non-inferior fidelity in downstream patient survival prediction. Future work should iterate upon and integrate such tools to enhance patient care.
△ Less
Submitted 3 April, 2024;
originally announced April 2024.
Brain tumour genetic network signatures of survival
Authors:
James K Ruffle,
Samia Mohinta,
Guilherme Pombo,
Robert Gray,
Valeriya Kopanitsa,
Faith Lee,
Sebastian Brandner,
Harpreet Hyare,
Parashkev Nachev
Abstract:
Tumour heterogeneity is increasingly recognized as a major obstacle to therapeutic success across neuro-oncology. Gliomas are characterised by distinct combinations of genetic and epigenetic alterations, resulting in complex interactions across multiple molecular pathways. Predicting disease evolution and prescribing individually optimal treatment requires statistical models complex enough to capt…
▽ More
Tumour heterogeneity is increasingly recognized as a major obstacle to therapeutic success across neuro-oncology. Gliomas are characterised by distinct combinations of genetic and epigenetic alterations, resulting in complex interactions across multiple molecular pathways. Predicting disease evolution and prescribing individually optimal treatment requires statistical models complex enough to capture the intricate (epi)genetic structure underpinning oncogenesis. Here, we formalize this task as the inference of distinct patterns of connectivity within hierarchical latent representations of genetic networks. Evaluating multi-institutional clinical, genetic, and outcome data from 4023 glioma patients over 14 years, across 12 countries, we employ Bayesian generative stochastic block modelling to reveal a hierarchical network structure of tumour genetics spanning molecularly confirmed glioblastoma, IDH- wildtype; oligodendroglioma, IDH-mutant and 1p/19q codeleted; and astrocytoma, IDH- mutant. Our findings illuminate the complex dependence between features across the genetic landscape of brain tumours, and show that generative network models reveal distinct signatures of survival with better prognostic fidelity than current gold standard diagnostic categories.
△ Less
Submitted 5 May, 2023; v1 submitted 15 January, 2023;
originally announced January 2023.
